📊 NRIX Key Takeaways
Is Nurix Therapeutics, Inc. (NRIX) a Good Investment?
Nurix is a pre-commercial biotech showing promising 54% revenue growth but facing unsustainable cash burn of $168.5M annually against only $67.7M in cash reserves. Losses are worsening significantly (up 36.6% YoY) despite revenue gains, indicating expenses are growing faster than commercialization can offset, creating an imminent capital crisis within 5 months at current burn rates.
Revenue grew 54.0%, but its small $15.29 million base remains insufficient to offset a $186.70 million operating loss and $171.47 million free-cash-flow deficit. The debt-free balance sheet and 6.34x current ratio provide resilience, yet persistent cash consumption and deeply negative returns make the fundamentals highly dependent on clinical progress, partnership funding, and future capital raises.
Nurix Therapeutics, Inc. Key Strengths (NRIX)
- Strong liquidity position with 6.34x current ratio and zero debt eliminates financial distress risk
- Revenue growing 54% YoY indicating successful early commercialization or partnership value
- Solid balance sheet with $402.6M equity and only $132.9M liabilities provides runway for operations
- Revenue increased 54.0% year over year
- Strong liquidity with a 6.34x current ratio
- Debt-free capital structure with $402.63 million of stockholders equity
NRIX Stock Risks: Nurix Therapeutics, Inc. Investment Risks
- Operating cash burn of $168.5M annualized against $67.7M cash creates critical runway crisis within 5 months requiring immediate capital raise
- Losses deteriorating despite revenue growth: net loss increased 36.6% YoY while revenue grew 54%, indicating expenses scaling faster than revenue
- Extreme negative margins (-1155% net, -1220% operating) demonstrate business is far from sustainability without massive revenue inflection
- Operating expenses vastly exceed revenue, producing a -1220.7% operating margin
- Free cash flow was negative $171.47 million, indicating substantial ongoing funding needs
- Cash and equivalents of $67.69 million are low relative to annual operating cash burn, creating financing and dilution risk
Key Metrics to Watch
- Quarterly revenue trajectory and commercial traction sustainability
- Monthly cash burn rate and path to cash flow breakeven
- Capital raise activity and dilution impact on equity
- Operating cash burn and available liquidity
- Revenue growth relative to research and development expenses
Nurix Therapeutics, Inc. (NRIX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 6.34x current ratio provides a solid financial cushion.
NRIX Profit Margin, ROE & Profitability Analysis
NRIX vs Healthcare Sector: How Nurix Therapeutics, Inc. Compares
How Nurix Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Nurix Therapeutics, Inc. Stock Overvalued? NRIX Valuation Analysis 2026
Based on fundamental analysis, Nurix Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Nurix Therapeutics, Inc. Balance Sheet: NRIX Debt, Cash & Liquidity
NRIX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Nurix Therapeutics, Inc.'s revenue has shown modest growth of 9% over the 5-year period. The most recent EPS of $-2.65 indicates the company is currently unprofitable.
NRIX Revenue Growth, EPS Growth & YoY Performance
NRIX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $9.0M | -$43.5M | $-0.52 |
| Q1 2026 | $6.3M | -$56.4M | $-0.67 |
| Q3 2025 | $7.9M | -$41.5M | $-0.67 |
| Q2 2025 | $12.1M | -$41.5M | $-0.52 |
| Q1 2025 | $16.6M | -$41.5M | $-0.67 |
| Q3 2024 | $12.6M | -$24.3M | $-0.67 |
| Q2 2024 | $12.1M | -$24.3M | $-0.45 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Nurix Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
NRIX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Nurix Therapeutics, Inc. (CIK: 0001549595)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Aug 5, 2026 | 4 | xslF345X06/wk-form4_1785970741.xml | View → |
| Aug 5, 2026 | 4 | xslF345X06/wk-form4_1785926375.xml | View → |
| Aug 4, 2026 | 4 | xslF345X06/wk-form4_1785894078.xml | View → |
| Aug 3, 2026 | 4 | xslF345X06/wk-form4_1785793916.xml | View → |
| Jul 30, 2026 | 4 | xslF345X06/wk-form4_1785448733.xml | View → |
❓ Frequently Asked Questions about NRIX
What is the AI rating for NRIX?
Nurix Therapeutics, Inc. (NRIX) has a Combined AI Grade of C from Claude (C) and ChatGPT (C) with 86% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are NRIX's key strengths?
Claude: Strong liquidity position with 6.34x current ratio and zero debt eliminates financial distress risk. Revenue growing 54% YoY indicating successful early commercialization or partnership value. ChatGPT: Revenue increased 54.0% year over year. Strong liquidity with a 6.34x current ratio.
What are the risks of investing in NRIX?
Claude: Operating cash burn of $168.5M annualized against $67.7M cash creates critical runway crisis within 5 months requiring immediate capital raise. Losses deteriorating despite revenue growth: net loss increased 36.6% YoY while revenue grew 54%, indicating expenses scaling faster than revenue. ChatGPT: Operating expenses vastly exceed revenue, producing a -1220.7% operating margin. Free cash flow was negative $171.47 million, indicating substantial ongoing funding needs.
What is NRIX's revenue and growth?
Nurix Therapeutics, Inc. reported revenue of $15.3M.
Does NRIX pay dividends?
Nurix Therapeutics, Inc. does not currently pay dividends.
Where can I find NRIX SEC filings?
Official SEC filings for Nurix Therapeutics, Inc. (CIK: 0001549595) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NRIX's EPS?
Nurix Therapeutics, Inc. has a diluted EPS of $-1.60.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is NRIX's fundamental grade?
Based on our AI fundamental analysis in August 2026, Nurix Therapeutics, Inc. has a C grade with 86% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is NRIX stock overvalued or undervalued?
Valuation metrics for NRIX: ROE of -43.9% (sector avg: 15%), net margin of -1,155.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is NRIX's AI grade for 2026?
Our dual AI analysis gives Nurix Therapeutics, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NRIX's free cash flow?
Nurix Therapeutics, Inc.'s operating cash flow is $-168.5M, with capital expenditures of $3.0M. FCF margin is -1,121.1%.
How does NRIX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,155.3% (avg: 12%), ROE -43.9% (avg: 15%), current ratio 6.34 (avg: 2).